| Would you like to help in some research on the regulation of what future AI-driven nanomedicines should look like? If so, researchers at the University of Bristol are looking for volunteers to discuss ethical and regulatory issues of using AI driven cancer therapies with swarm behaviour through a series of interviews. | |
| The research is part of the SWARM study – Small robots With collective behaviour as AI-driven cancer therapies; building Regulations for future nanoMedicines. | |
| The researchers are looking for: | |
|
|
| Volunteers must be over the age of 18 years old to take part. We would love to hear from you. You can find out more about the study on our SWARM study webpage or by contacting Matimba Swana at matimba.swana@bristol.ac.uk. | |
| If you would like to take part please complete this Expression of Interest Form. | |
About the SWARM study |
| Cancer occurs when abnormal cells divide in an uncontrolled way. Many cancers can be cured. But in some people cancer can return. Cancer drugs, such as chemotherapy, need to be able to kill all the cancer cells, but this means they can also kill healthy cells. | |
| Nanomedicine is the medical application of nanotechnology which works on tiny scales called ‘nanometres’ (one-billionth of a metre). Nanoparticles are nanosized particles that can assist the delivery of chemotherapy drugs to cancer cells. Scientists and Engineers can use simulations for selecting nanoparticles so drugs can more effectively reach the tumour while avoiding side effects. | |
| Nanoswarms | |
| Using simulations, scientists and engineers are working on adding swarm behaviour (present in social animals such as birds, ants, fish and termites) to nanoparticles and tiny robots (nanobots). Nanoswarms are multiple nanoparticles or nanobots that can interact with each other or their environment to achieve a task (e.g. deliver chemotherapy to a tumour without killing healthy cells), exhibiting collective behaviour inspired by swarm behaviour. | |
| SWARM study – aim & research question | |
| This project is investigating the ethics and regulations of the first in-human clinical trial of nanoswarms. We will be using interviews initially and focus groups in the next phase to explore the attitudes of stakeholders towards this swarm technology in healthcare, combined with ethical/legal analysis to consider how swarm medicine should be regulated in clinical trials. | |
| The aim is to explore how nanoswarm medicine should be regulated once this technology is available for first-in human clinical trials. | |
| Researchers | |
| This study is being organised by Matimba Swana, PhD student in the Trustworthy Autonomous Systems in Functionality Node and Academic Supervisors; Dr. Sabine Hauert, Reader (Associate Professor) in Swarm Engineering and Prof. Jonathan Ives, Professor of Empirical Bioethics & Deputy Director of Centre for Ethics in Medicine. | |
Would you like to participate? |
|
| If you are aged 18 or over, we would love to hear from you. For the interviews we are looking for oncology healthcare professionals or oncology patients or those working in drug delivery regulation or in nanomedicine research. You do not need to have any previous knowledge of nanoswarms to participate as we will show you case studies to introduce you to the technologies. | |
| Your contribution would be very helpful! For more details please contact Matimba Swana at matimba.swana@bristol.ac.uk OR complete this Expression of Interest form for interviews. | |
| We are still in the first phase of this study, so will not start interviews until later in the year, but please complete the Expression of Interest form for interviews and we will be in touch to schedule an interview. We will start recruiting for focus groups in early 2023. | |
Five fun facts |
|
|
|
| The SWARM study is part of a larger UKRI-funded PhD which is part of the Trustworthy Autonomous Systems Node in Functionality research programme, which is a multidisciplinary collaboration between ethicists, sociologists, computer scientists and engineers working together to produce guidelines for the development of trustworthy autonomous systems with evolving functionality. | |
Research Ethics Approval |
|
| This project has been reviewed and approved by the University of Bristol Faculty of Engineering Research Ethics Committee (Ref: 11141). | |
| Find out more before participating from these PDFs: | |
| SWARM study summary | |
| SWARM flyer Interviews | |
| Participant Information Sheet for Interviews | |
| SWARM flyer focus groups | |
| Participant Information for Focus Groups (will be live once interviews are completed) | |
| Expression of Interest for Focus Groups (will be live once interviews are completed) |
News
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from [...]
New injectable treatment helps the brain rebuild after stroke
Biomedical engineers at Duke University have created an injectable biomaterial that may help the brain recover from damage left behind by an ischemic stroke. In experiments with mice, the material transformed the cavity created [...]
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
Is there a summer COVID-19 surge this year? Yep, it’s ramping up again
Hantavirus. Ebola. West Nile. Measles. And, of course, cyclospora — that stomach parasite making people miserable across the country. Americans have plenty to worry about this summer. But remember COVID-19? It may not be [...]
Natural Compound in Broccoli Could Help Treat a Rare, Incurable Neurological Disease
Swinburne researchers have discovered how broccoli could help treat an extremely rare and incurable disease that affects only about 200 Australians. A naturally occurring compound in broccoli is being investigated as a possible treatment [...]
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]















